2-Methyl-DMT

2-Methyl-DMT, or 2-Me-DMT, also known as 2-methyl-N,N-dimethyltryptamine or as 2,N,N-trimethyltryptamine (2,N,N-TMT or 2-TMT), is a psychoactive drug of the tryptamine family related to the psychedelic drug dimethyltryptamine (DMT). It is not a conventional psychedelic, but instead produces tactile enhancement and auditory distortion. The drug was described by Alexander Shulgin and reported in his book TiHKAL (Tryptamines I Have Known and Loved).

Use and effects 2-Methyl-DMT is claimed to show psychoactive effects at a dose of 50 to 100mg orally, but these are relatively mild compared to other similar drugs. This suggests that while the 2-methyl group has blocked the binding of metabolic enzymes, it is also interfering with binding to the 5-HT2A receptor target that mediates the hallucinogenic effects of these drugs. The duration of 2-methyl-DMT is 4 to 6hours.

The specific effects produced by 2-methyl-DMT included tingling, mild stomach rumbling, mild relaxation, skin "alerting" especially on the head and neck, bodily/tactile activation and heightened sensitivity, auditory distortion, and altered tonal perception. There were no visuals, no cloudiness of thought processes, no motor impairment, but sexual activity was said to be enhanced. There were no changes in appetite, no gastrointestinal problems, and no after-effects the next day. The drug was described as not being a psychedelic or psychostimulant, but instead being a specific "tactile stimulant" and sexual enhancer.

Interactions

Pharmacology Pharmacodynamics Its affinities (Ki) for the serotonin 5-HT1A and 5-HT2A receptor were 4,598nM and 15,037nM, respectively. These affinities were dramatically lower than those of dimethyltryptamine (DMT) in the same study, which were 87nM and 1,513nM, respectively. Hence, 2-methyl-DMT appears to show approximately 53- and 10-fold lower affinities for the serotonin 5-HT1A and 5-HT2A receptors compared to DMT. In addition, unlike DMT, 2-methyl-DMT failed to activate the serotonin 5-HT1A and 5-HT2A receptors. Similarly, 2-methyl-DMT showed profoundly reduced serotonin receptor agonism in the rat uterus and fundus strip. Despite the preceding findings however, 2-methyl-DMT robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and does so to a similar magnitude as psilocin and 5-MeO-DMT.

In studies of other 2-methyltryptamines, specifically 2-methyl-5-MeO-DALT and 2-methyl-5-F-DALT, these compounds had variably reduced affinities for serotonin receptors and, in contrast to 2-methyl-DMT, did not produce the head-twitch response.

Chemistry Synthesis The chemical synthesis of 2-methyl-DMT has been described.

Analogues Analogues of 2-methyl-DMT include dimethyltryptamine (DMT), 2-methyltryptamine (2-methyl-T), 2-methyl-DET, 2-methyl-AMT, 2-Me-5-MeO-DMT (5-MeO-2,N,N-TMT), 4-methyl-DMT, 5-methyl-DMT, 6-methyl-DMT, and 7-methyl-DMT.

History 2-Methyl-DMT was first described in the scientific literature by R. B. Barlow and I. Khan by 1959. Subsequently, it was described in greater detail by Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved) in 1997.

Society and culture Legal status Canada 2-Methyl-DMT is not an explicitly nor implicitly controlled substance in Canada as of 2025.

Sweden Sweden's public health agency suggested classifying 2-methyl-DMT as a hazardous substance, on May 15, 2019.

United States 2-Methyl-DMT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

2-Methyl-DMT

Bron en licentie